Novartis buys CoStim as big pharmas boost their cancer immunotherapy arsenals
This article was originally published in Scrip
Executive Summary
Novartis has bought private US company CoStim Pharmaceuticals for an undisclosed sum in a transaction that demonstrates the increasing allure of cancer immunotherapy to big pharma as a therapeutic strategy.